Screening for type 2 diabetes: a short report for the National Screening Committee.

Area of Science:

• Public Health
• Endocrinology
• Screening Programs

Background:

• Increasing prevalence of type 2 diabetes mellitus (T2DM) due to lifestyle factors and demographic shifts.
• Undiagnosed T2DM can lead to severe complications, including retinopathy and cardiovascular events.
• Raised blood glucose levels are an indicator for potential undiagnosed diabetes.

Purpose of the Study:

• To provide an updated review for the UK National Screening Committee (NSC) on the effectiveness of T2DM screening.
• To assess T2DM screening against established NSC criteria for population screening programmes.

Main Methods:

• Literature search restricted to evidence from 2009 to early 2012, with updates.
• Databases searched include MEDLINE, EMBASE, and Science Citation Index.
• Evaluation of screening against NSC criteria, including evidence of benefit and optimisation of management.

Main Results:

• Population screening for T2DM does not meet all NSC criteria, particularly regarding optimisation of management and evidence of benefit from randomized controlled trials.
• Trials such as the Ely and ADDITION studies did not demonstrate clear cardiovascular benefits from screening or intensive management of screen-detected T2DM.
• Issues with staffing, facilities, and consideration of prevention strategies were also noted.
• Risk factor-based selection using tools like QDiabetes or FINDRISC followed by blood glucose testing is a potential approach.
• HbA1c testing offers advantages but has limitations in sensitivity; oral glucose tolerance tests are more sensitive but less practical.

Conclusions:

• The case for T2DM screening is weaker than previously, primarily due to a lack of demonstrated cardiovascular benefit in recent trials.
• Population screening for T2DM does not fully satisfy NSC criteria.
• Selective screening, integrated into overall vascular risk assessment, presents a more viable option.